{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:26:49Z","timestamp":1772252809224,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>It is not established whether SARS-CoV-2 (COVID-19) patients with movement disorders, are at greater risk for more serious outcomes than the larger COVID-19 population beyond the susceptibility associated with greater age. We reviewed electronic health records and conducted telephone interviews to collect the demographics and clinical outcomes of patients seen at our Movement Disorders Center who tested positive for COVID-19 from 8 March 2020 through 6 June 2020. Thirty-six patients were identified, 23 men and 13 women, median age of 74.5 years. They primarily carried diagnoses of idiopathic Parkinson disease (n = 22; 61%) and atypical parkinsonism (n = 7; 19%) with the balance having other diagnoses. Twenty-seven patients (75%) exhibited alteration in mental status and fifteen (42%) had abnormalities of movement as common manifestations of COVID-19; in 61% and 31%, respectively, these were the presenting symptoms of the disease. Sixty-seven percent of patients in our cohort required hospitalization, and the mortality rate was 36%. These data demonstrate that in patients with movement disorders, the likelihood of hospitalization and death after contracting COVID-19 was greater than in the general population. Patients with movement disorders frequently presented with altered mental status, generalized weakness, or worsening mobility but not anosmia.<\/jats:p>","DOI":"10.3390\/geriatrics5030054","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T10:22:23Z","timestamp":1600424543000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center"],"prefix":"10.3390","volume":"5","author":[{"given":"Joy Antonelle","family":"de Marcaida","sequence":"first","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-2692","authenticated-orcid":false,"given":"Jeffrey","family":"Lahrmann","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duarte","family":"Machado","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Bluth","sequence":"additional","affiliation":[{"name":"Hartford Neurology LLC, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Dagostine","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Moro-de Casillas","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bortan","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulada","family":"Kanchana","sequence":"additional","affiliation":[{"name":"Chase Family Movement Disorders Center, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Alberts","sequence":"additional","affiliation":[{"name":"Ayer Neuroscience Institute, Hartford HealthCare, Hartford, CT 06066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"ref_5","first-page":"357","article-title":"Impact of the COVID-19 Pandemic on Parkinson\u2019s Disease and Movement Disorders","volume":"7","author":"Papa","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JPD-202038","article-title":"The impact of the COVID-19 pandemic on Parkinson\u2019s disease: Hidden sorrows and emerging opportunities","volume":"10","author":"Helmich","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref_7","first-page":"105","article-title":"COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson\u2019s Disease Patient Care","volume":"13","author":"Bhidayasiri","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S2468-2667(20)30146-8","article-title":"The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study","volume":"5","author":"Hewitt","year":"2020","journal-title":"Lancet Public Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JPD-202105","article-title":"Multimorbidity and Frailty: Tackling Complexity in Parkinson\u2019s Disease","volume":"10","author":"Tenison","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/mds.28084","article-title":"SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration","volume":"35","author":"Lippi","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-202073","article-title":"COVID-19 and Parkinson\u2019s Disease: Are We Dealing with Short-term Impacts or Something Worse?","volume":"10","author":"Victorino","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"ref_12","unstructured":"DPH, C. (2020, June 06). Available online: https:\/\/portal.ct.gov\/-\/media\/Coronavirus\/CTDPHCOVID19summary6062020.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.28088","article-title":"Parkinson\u2019s Disease and COVID-19: Perceptions and Implications in Patients and Caregivers","volume":"35","author":"Prasad","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/mds.28170","article-title":"Effects of COVID-19 on Parkinson\u2019s Disease Clinical Features: A Community-Based Case-Control Study","volume":"35","author":"Cilia","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/mds.28104","article-title":"Outcome of Parkinson\u2019s Disease Patients Affected by COVID-19","volume":"35","author":"Antonini","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12603-020-1389-1","article-title":"Clinical Presentation of COVID19 in Dementia Patients","volume":"24","author":"Bianchetti","year":"2020","journal-title":"J. Nutr. Health Aging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20\u2009133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"ref_18","unstructured":"DPH, C. (2020, June 10). Available online: https:\/\/portal.ct.gov\/-\/media\/Coronavirus\/CTDPHCOVID19summary6042020.pdf?la=en."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocn.2020.05.017","article-title":"Neurological manifestations and complications of COVID-19: A literature review","volume":"77","author":"Ahmad","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.parkreldis.2020.05.008","article-title":"Rapid worsening in Parkinson\u2019s disease may hide COVID-19 infection","volume":"75","author":"Hainque","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Brenner, S.R. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J. Med. Virol., 2020.","DOI":"10.1002\/jmv.26030"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106004","DOI":"10.1016\/j.ijantimicag.2020.106004","article-title":"Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment","volume":"55","author":"Smieszek","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.msard.2020.102163","article-title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: Multiple sclerosis, parkinsonism and cognitive impairment","volume":"42","author":"Rejdak","year":"2020","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/5\/3\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:11:18Z","timestamp":1760177478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/5\/3\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["geriatrics5030054"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics5030054","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202008.0618.v1","asserted-by":"object"}]},"ISSN":["2308-3417"],"issn-type":[{"value":"2308-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}